DNA Double-Strand Break Repair Inhibitors as Cancer Therapeutics

Srivastava, Mrinal and Raghavan, Sathees C (2015) DNA Double-Strand Break Repair Inhibitors as Cancer Therapeutics. In: CHEMISTRY & BIOLOGY, 22 (1). pp. 17-29.

PDF che_bio_22-1_17_2015.pdf - Published Version Restricted to Registered users only Download (1MB) | Request a copy

Abstract

Among DNA damages, double-strand breaks (DSBs) are one of the most harmful lesions to a cell. Failure in DSB repair could lead to genomic instability and cancer. Homologous recombination (HR) and nonhomologous end joining (NHEJ) are major DSB repair pathways in higher eukaryotes. It is known that expression of DSB repair genes is altered in various cancers. Activation of DSB repair genes is one of the reasons for chemo-and radioresistance. Therefore, targeting DSB repair is an attractive strategy to eliminate cancer. Besides, therapeutic agents introduce breaks in the genome as an intermediate. Therefore, blocking the residual repair using inhibitors can potentiate the efficacy of cancer treatment. In this review, we discuss the importance of targeting DSB repair pathways for the treatment of cancer. Recent advances in the development of DSB repair inhibitors and their clinical relevance are also addressed.

Item Type:	Journal Article
Publication:	CHEMISTRY & BIOLOGY
Publisher:	CELL PRESS
Additional Information:	Copy right for this article belongs to the CELL PRESS, 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
Department/Centre:	Division of Biological Sciences > Biochemistry
Date Deposited:	05 Mar 2015 12:58
Last Modified:	05 Mar 2015 12:58
URI:	http://eprints.iisc.ac.in/id/eprint/51015

Actions (login required)

View Item